Artificial Intelligence for Clinical Trial Design

Aug. 6, 2019

Harrer S, Shah P, Antony B, Hu J. Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci. 2019 Aug;40(8):577-591. doi: 10.1016/ PMID: 31326235.


Clinical trials consume the latter half of the 10 to 15 year, 1.5-2.0 billion USD, development cycle for bringing a single new therapy to market. Hence, a failed trial sinks not only the investment into the trial itself but also the preclinical development costs, rendering the loss per failed clinical trial at 800 million to 1.4 billion USD. Suboptimal patient cohort selection and recruiting techniques, paired with the inability to monitor patients effectively during trials, are two of the main causes for high trial failure rates:  In this review article published in Cell press journal Trends in Pharmacological Science explains how recent advances in artificial intelligence (AI) can be used to reshape key steps of clinical trial design towards increasing trial success rates.

Stefan Harrer , Pratik ShahBhavna AntonyJianying Hu

IBM Research, IBM Research Australia Lab, 3006 Melbourne, VIC, Australia 

 Massachusetts Institute of Technology, 02139 Cambridge, MA, USA 

 IBM Research, IBM T.J. Watson Research Center, 10598 Yorktown Heights, NY, USA

Related Content